CFTR and chronic bronchitis: Noting that once-daily oral administration of roflumilast is indicated for use in patients with COPD and chronic bronchitis [26], the target population of CFTR modulator therapy in COPD [19, 27, 28], we evaluated the effect of roflumilast administered to mice by oral gavage over time.